Brown Lauren T L, Cull Megan E, Xue Lihua, Winn Louise M
Department of Biomedical and Molecular Sciences, Queen's University at Kingston, Kingston, Canada.
School of Environmental Studies, Queen's University at Kingston, Kingston, Canada.
J Appl Toxicol. 2025 Dec;45(12):2624-2640. doi: 10.1002/jat.4860. Epub 2025 Jul 21.
Valproic acid (VPA) is an antiepileptic and mood-stabilizing drug that causes teratogenic effects, including neural tube defects (NTDs), when taken during pregnancy. Although animal models are widely used to study VPA teratogenicity, most rely on litter means, which overlook variability within the litter. In litter-bearing species like mice, fetal development can vary by sex, uterine horn location, and intrauterine position. This study examined whether these intralitter variables affect fetal and placental outcomes following VPA exposure. Pregnant CD-1 mice received a subcutaneous injection of saline (vehicle control), 400 mg/kg, or 600 mg/kg VPA on gestational day (GD) 9 and were euthanized on GD 18. Fetuses and placentas were collected, weighed, and stratified by exposure, NTD status, sex, uterine horn location, and intrauterine position. Fetal and placental weights were normalized to maternal weight gain and live litter size or the number of live fetuses in each uterine horn. VPA exposure produced a clear dose-dependent effect, with 600 mg/kg significantly increasing postimplantation losses and NTD frequency. These effects were further influenced by intralitter variables, particularly sex and uterine horn location. Fetal weight increased at 400 mg/kg VPA but was unchanged at 600 mg/kg, while placental weight decreased and placental efficiency increased at both doses, suggesting possible compensatory adaptations. At 600 mg/kg VPA, sex differences in placental weight and efficiency were lost, and fetuses in the left uterine horn were significantly lighter than those in the right, indicating location-dependent susceptibility. Intrauterine position did not significantly affect outcomes. These findings demonstrate that intralitter variables influence fetal and placental responses to VPA and underscore the need to account for these factors to improve the translational relevance of developmental toxicology studies.
丙戊酸(VPA)是一种抗癫痫和情绪稳定药物,孕期服用会导致致畸作用,包括神经管缺陷(NTDs)。尽管动物模型被广泛用于研究VPA致畸性,但大多数依赖窝均值,这忽略了窝内的变异性。在小鼠等产仔物种中,胎儿发育会因性别、子宫角位置和子宫内位置而有所不同。本研究调查了这些窝内变量是否会影响VPA暴露后的胎儿和胎盘结局。怀孕的CD-1小鼠在妊娠第9天接受皮下注射生理盐水(溶剂对照)、400mg/kg或600mg/kg VPA,并在妊娠第18天安乐死。收集胎儿和胎盘,称重,并按暴露情况、NTD状态、性别、子宫角位置和子宫内位置进行分层。将胎儿和胎盘重量标准化为母体体重增加量和存活窝仔数或每个子宫角内的存活胎儿数。VPA暴露产生了明显的剂量依赖性效应,600mg/kg显著增加着床后损失和NTD频率。这些效应进一步受到窝内变量的影响,特别是性别和子宫角位置。VPA剂量为400mg/kg时胎儿体重增加,但600mg/kg时未发生变化,而两个剂量下胎盘重量均降低且胎盘效率增加,表明可能存在代偿性适应。在VPA剂量为600mg/kg时,胎盘重量和效率的性别差异消失,左子宫角的胎儿明显比右子宫角的胎儿轻,表明存在位置依赖性易感性。子宫内位置对结局没有显著影响。这些发现表明窝内变量会影响胎儿和胎盘对VPA的反应,并强调需要考虑这些因素以提高发育毒理学研究的转化相关性。